GRI BIO INC(GRI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GRI GRI BIO INC

Trading 02-24 11:36:26 EST

2.36

+0.03

+1.29%

High2.41	Low2.32	Vol9.51K
Open2.37	D1 Closing2.33	Amplitude3.82%
Mkt Cap3.41M	Tradable Cap752.06K	Total Shares1.45M
T/O22.38K	T/O Rate2.98%	Tradable Shares318.67K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GRI","market":"US","secType":"STK","nameCN":"GRI BIO INC","latestPrice":2.36,"timestamp":1771950927092,"preClose":2.33,"halted":0,"volume":9507,"delay":0,"changeRate":0.01287553648068661,"floatShares":318671,"shares":1445000,"eps":-121.8,"marketStatus":"Trading","change":0.03,"latestTime":"02-24 11:36:26 EST","open":2.37,"high":2.41,"low":2.321,"amount":22380.630248399997,"amplitude":0.038197,"askPrice":2.4,"askSize":66,"bidPrice":2.36,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-121.8,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771966800000},"marketStatusCode":2,"symbolChange":{"newSymbol":"RDOG","executeDate":"2020-01-02"},"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.33,"sharesOutstanding":1100000,"nav":47.93,"aum":52503274.57,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":2.47,"preClose":2.33,"latestTime":"08:34 EST","volume":181,"amount":437.1842144,"timestamp":1771940077432,"change":0.14,"changeRate":0.060086,"amplitude":0.094292},"postHourTrading":{"tag":"盘后","latestPrice":2.33,"preClose":2.33,"latestTime":"19:41 EST","volume":142,"amount":333.92,"timestamp":1771893697017,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.370966},"requestUrl":"/m/hq/s/GRI","defaultTab":"news","newsList":[{"id":"2612468964","title":"GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2612468964","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612468964?lang=en_us&edition=fundamental","pubTime":"2026-02-17 22:15","pubTimestamp":1771337700,"startTime":"0","endTime":"0","summary":"Access the “What This Means” segment here LA JOLLA, CA, Feb.  17, 2026  (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/17/3239401/0/en/GRI-Bio-CEO-Marc-Hertz-Featured-in-Virtual-Investor-What-This-Means-Segment.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GRI","BK4007"],"gpt_icon":0},{"id":"2609067103","title":"GRI Bio to Present at Webull Financial Corporate Connect Webinar Series","url":"https://stock-news.laohu8.com/highlight/detail?id=2609067103","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609067103?lang=en_us&edition=fundamental","pubTime":"2026-02-05 22:15","pubTimestamp":1770300922,"startTime":"0","endTime":"0","summary":"Gri Bio Inc. will participate in the Corporate Connect Webinar Series hosted by Webull Financial. The virtual event is scheduled for February 11, 2026, at 1:00 PM EST, with Marc Hertz, PhD, President, Chief Executive Officer and Director, presenting on behalf of the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gri Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on February 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDLCLbBZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210149790.SGD","BK4585","LU2095319765.USD","LU2210150020.SGD","BK4127","GRI","SG9999014005.SGD","SG9999014021.USD","LU0314104364.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014039.USD","IE00BGHQF748.EUR","SG9999014013.SGD","BK4007","IE00B3QW5Z07.USD","BK4112","BK4139"],"gpt_icon":0},{"id":"2608367528","title":"GRI Bio raises $14.5 mln to fund operations into Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2608367528","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608367528?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:56","pubTimestamp":1770213380,"startTime":"0","endTime":"0","summary":"GRI Bio raises $14.5 mln to fund operations into Q1 2027OverviewBiotechnology company raised $14.5 mln in gross proceeds to fund operations into Q1 2027Company announced positive Phase 2a data for GRI","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nL1N3Z00R6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","GRI"],"gpt_icon":0},{"id":"2608362074","title":"Gri Bio Inc. reports FY 2025 cash and cash equivalents of USD 8.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2608362074","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608362074?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:45","pubTimestamp":1770212717,"startTime":"0","endTime":"0","summary":"Gri Bio Inc. reported full year 2025 financial results, ending the year with cash and cash equivalents of approximately USD 8.2 million. In January 2026, the company raised an additional USD 6.5 million in gross proceeds through its At The Market offering, strengthening its balance sheet. Gri Bio expects its current cash position to fund operations into the first quarter of 2027. On the business front, Gri Bio highlighted positive topline results from its Phase 2a clinical study of GRI-0621 in idiopathic pulmonary fibrosis , reinforcing clinical proof-of-concept and demonstrating suppression of pro-fibrotic immune phenotypes. Additionally, new RNA-sequencing gene expression data showed a direct impact on fibrosis and lung repair biology. The company is progressing GRI-0803, focused on autoimmune indications with high unmet need, through IND-enabling studies, expanding its pipeline in autoimmune diseases. Management emphasized a focus on disciplined clinical execution and capital manage","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL6zCCsP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SG9999014013.SGD","BK4112","BK4007","LU0314104364.USD","SG9999014005.SGD","SG9999014039.USD","GRI","NDAQ","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU2095319765.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","SG9999014021.USD","BK4588"],"gpt_icon":0},{"id":"2607076513","title":"Gri Bio Warns of Ongoing Internal Control Weaknesses That Could Threaten Financial Reporting Reliability and Investor Confidence","url":"https://stock-news.laohu8.com/highlight/detail?id=2607076513","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607076513?lang=en_us&edition=fundamental","pubTime":"2026-01-31 14:00","pubTimestamp":1769839228,"startTime":"0","endTime":"0","summary":"Gri Bio, Inc. (GRI) has disclosed a new risk, in the Accounting & Financial Operations category. Gri Bio, Inc. faces an ongoing control environment...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gri-bio-warns-of-ongoing-internal-control-weaknesses-that-could-threaten-financial-reporting-reliability-and-investor-confidence?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gri-bio-warns-of-ongoing-internal-control-weaknesses-that-could-threaten-financial-reporting-reliability-and-investor-confidence?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GRI","BK4007","BK4139"],"gpt_icon":0},{"id":"2607145170","title":"BRIEF-GRI Bio May Offer Up To $250 Million In Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2607145170","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607145170?lang=en_us&edition=fundamental","pubTime":"2026-01-30 19:09","pubTimestamp":1769771358,"startTime":"0","endTime":"0","summary":"BRIEF-GRI Bio May Offer Up To $250 Million In Securities - SEC FilingJan 30 (Reuters) - GRI Bio Inc GRI.O:GRI BIO INC - MAY OFFER UP TO $250 MILLION IN SECURITIES - SEC FILINGSource text: [ID:n0001824293-26-000028]Further company coverage: GRI.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nFWN3YV0IG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRI","BK4139","BK4007"],"gpt_icon":0},{"id":"2607014366","title":"GRI Bio Inc - May Offer up to $250 Mln in Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2607014366","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607014366?lang=en_us&edition=fundamental","pubTime":"2026-01-30 19:07","pubTimestamp":1769771223,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nFWN3YV0IG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GRI","BK4007"],"gpt_icon":0},{"id":"2606717098","title":"GRI Bio Inc trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2606717098","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606717098?lang=en_us&edition=fundamental","pubTime":"2026-01-28 22:35","pubTimestamp":1769610928,"startTime":"0","endTime":"0","summary":"09:32 EST GRI Bio (GRI) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving b...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gri-bio-inc-trading-halted-volatility-trading-pause-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gri-bio-inc-trading-halted-volatility-trading-pause-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GRI","BK4007","BK4139"],"gpt_icon":0},{"id":"2606471490","title":"GRI Bio Inc - GRI-0621 Shows Well-Tolerated Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2606471490","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606471490?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:45","pubTimestamp":1769607912,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nFWN3YT0KS:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","GRI"],"gpt_icon":0},{"id":"2606714155","title":"GRI Bio Reports Positive Phase 2a Results for GRI-0621 in Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2606714155","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606714155?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:45","pubTimestamp":1769607910,"startTime":"0","endTime":"0","summary":"Gri Bio Inc. has announced new data from its recently completed Phase 2a clinical study of GRI-0621 in patients with Idiopathic Pulmonary Fibrosis . The results, which have already been presented, indicate that GRI-0621 met its primary endpoint by demonstrating favorable safety and tolerability. The study also met multiple secondary endpoints indicative of disease-modifying activity, and exploratory data showed that twice as many GRI-0621-treated subjects experienced no decline in forced vital capacity at 12 weeks compared to standard of care alone. Newly reported gene expression analysis revealed significant improvements in genes associated with lung injury, fibrosis progression, and tissue repair among treated subjects compared to placebo. These findings suggest a direct impact of GRI-0621 on the underlying biology of IPF.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDLQ8RWZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRI","IE00BGHQF748.EUR","BK4585","LU2095319765.USD","LU0314104364.USD","LU2210150020.SGD","SG9999014039.USD","BK4112","SG9999014021.USD","SG9999014013.SGD","SG9999014005.SGD","BK4007","IE00BKPKM429.USD","NDAQ","LU2210149790.SGD","BK4588","BK4139","IE00B3QW5Z07.USD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2606712430","title":"GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF","url":"https://stock-news.laohu8.com/highlight/detail?id=2606712430","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606712430?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:45","pubTimestamp":1769607900,"startTime":"0","endTime":"0","summary":"Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan.  28, 2026  (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/28/3227630/0/en/GRI-Bio-Delivers-Compelling-New-Phase-2a-Gene-Expression-Data-Demonstrating-Improvements-in-Key-Drivers-of-Fibrosis-and-Lung-Repair-in-IPF.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRI","BK4139","BK4007","FVC"],"gpt_icon":0},{"id":"2606924243","title":"GRI Bio Secures New U.S. Patent Covering Novel Compound Structures for Immune Modulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2606924243","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606924243?lang=en_us&edition=fundamental","pubTime":"2026-01-26 21:30","pubTimestamp":1769434217,"startTime":"0","endTime":"0","summary":"GRI Bio Inc. announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 12,528,775, granting composition-of-matter claims for a new class of proprietary compounds featuring pyrrolidine, piperidine, or azepane ring systems. The patent provides additional intellectual property protection for the company's platform of immunomodulators aimed at inflammatory, fibrotic, and autoimmune diseases. According to GRI Bio, this newly issued patent strengthens the company's IP estate by securing independent protection for a unique subset of its chemistry platform.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gri Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on January 26, 2026, and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL1v4jjC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK4139","GRI","LU0314104364.USD","SG9999014039.USD","LU2095319765.USD","IE00B64PRP62.GBP","SG9999014013.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","BK4007","NDAQ","BK4112","BK4585","SG9999014005.SGD","BK4588"],"gpt_icon":0},{"id":"2605281069","title":"NASDAQ TRADE HALT CONTINUES  HALT NEWS PENDING AT 07:59 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2605281069","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605281069?lang=en_us&edition=fundamental","pubTime":"2026-01-24 08:59","pubTimestamp":1769216388,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT CONTINUES  HALT NEWS PENDING AT 07:59 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260124:nAQN2LJ3SE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","GRI"],"gpt_icon":0},{"id":"2605328484","title":"GRI Bio Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2605328484","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605328484?lang=en_us&edition=fundamental","pubTime":"2026-01-24 08:50","pubTimestamp":1769215850,"startTime":"0","endTime":"0","summary":"19:50 EST GRI Bio (GRI) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking fina...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gri-bio-inc-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gri-bio-inc-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GRI","BK4139","BK4007"],"gpt_icon":0},{"id":"2605435688","title":"BRIEF-Gri Bio Announces Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2605435688","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605435688?lang=en_us&edition=fundamental","pubTime":"2026-01-22 05:41","pubTimestamp":1769031682,"startTime":"0","endTime":"0","summary":"BRIEF-Gri Bio Announces Reverse Stock SplitJan 21 (Reuters) - GRI Bio Inc GRI.O:GRI BIO ANNOUNCES REVERSE STOCK SPLITGRI BIO INC - ANNOUNCES 1-FOR-28 REVERSE STOCK SPLITSource text: ID:nGNX2BCVhmFurther company coverage: GRI.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nTUA47TQ9P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GRI","BK4007"],"gpt_icon":0},{"id":"2605438429","title":"GRI Bio Enacts 1-for-28 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2605438429","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605438429?lang=en_us&edition=fundamental","pubTime":"2026-01-22 05:01","pubTimestamp":1769029267,"startTime":"0","endTime":"0","summary":"GRI Bio, Inc. has announced a 1-for-28 reverse stock split of its common stock, effective January 23, 2026. The company's shares will begin trading on a split-adjusted basis on January 26, 2026, under the current ticker symbol \"GRI.\" The move is intended to increase the share price and help the company regain compliance with Nasdaq's minimum bid price requirement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gri Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on January 21, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL5Dnhf1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014021.USD","SG9999014013.SGD","IE00B3QW5Z07.USD","LU2210149790.SGD","LU2210150020.SGD","BK4007","LU0314104364.USD","BK4588","IE00BGHQF748.EUR","LU2095319765.USD","BK4112","BK4585","GRI","IE00BKPKM429.USD","SG9999014005.SGD","NDAQ","BK4139","SG9999014039.USD"],"gpt_icon":0},{"id":"2603996871","title":"Nasdaq Warns Gri Bio Over Stockholders’ Equity Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2603996871","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603996871?lang=en_us&edition=fundamental","pubTime":"2026-01-16 21:01","pubTimestamp":1768568485,"startTime":"0","endTime":"0","summary":"Gri Bio Inc. recently received a notice from the Nasdaq Stock Market LLC that it has conditionally regained compliance with the Nasdaq Listing Rule 5550, which requires companies to maintain stockholders' equity of at least $2.5 million. The company had previously been notified of non-compliance based on its financial filings for the quarter ended September 30, 2025. However, if Gri Bio Inc. fails to meet this equity requirement in future reports, its shares may once again face the risk of delisting from the Nasdaq Capital Market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gri Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDLb9LC9Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRI","BK4139","BK4007"],"gpt_icon":0},{"id":"2603998945","title":"Gri Bio Inc. Held Special Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2603998945","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603998945?lang=en_us&edition=fundamental","pubTime":"2026-01-15 23:15","pubTimestamp":1768490148,"startTime":"0","endTime":"0","summary":"Gri Bio Inc. held a special meeting of stockholders on January 15, 2026. Stockholders approved an amendment to the company's certificate of incorporation to authorize a reverse stock split of common stock at a ratio to be determined by the board of directors within a specified range. Stockholders also approved the option to postpone or adjourn the meeting if necessary to solicit additional proxies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gri Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 15, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDL3NywLC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","GRI"],"gpt_icon":0},{"id":"2601868364","title":"GRI Bio Reports Positive Phase 2a Results for GRI-0621 in Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2601868364","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601868364?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:00","pubTimestamp":1767877228,"startTime":"0","endTime":"0","summary":"Gri Bio Inc. has announced additional positive data from its Phase 2a clinical trial evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis . The randomized, double-blind, placebo-controlled study enrolled 35 subjects and assessed safety, tolerability, pharmacokinetics, and pharmacodynamic activity over 12 weeks of once-daily oral administration. New immune profiling data from bronchoalveolar lavage fluid and peripheral blood mononuclear cells demonstrated inhibition of invariant natural killer T  cell activity and a shift towards an anti-fibrotic immune profile. These results confirm the disease-modifying mechanism of GRI-0621 and reinforce earlier findings related to fibrosis resolution, lung repair, and improved lung function. The results have already been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL2ByP40:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014013.SGD","LU2210150020.SGD","GRI","SG9999014039.USD","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014021.USD","BK4112","BK4588","SG9999014005.SGD","IE00B64PRP62.GBP","LU0314104364.USD","BK4139","BK4007","NDAQ","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2601364845","title":"GRI Bio Announces Additional Positive Data From Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621","url":"https://stock-news.laohu8.com/highlight/detail?id=2601364845","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601364845?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:00","pubTimestamp":1767877206,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA36FB92:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GRI","BK4139","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gribio.com","stockEarnings":[{"period":"1week","weight":0.0087},{"period":"1month","weight":-0.5866},{"period":"3month","weight":-0.9596},{"period":"6month","weight":-0.9418},{"period":"1year","weight":-0.9882},{"period":"ytd","weight":-0.6628}],"compareEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0109},{"period":"6month","weight":0.0553},{"period":"1year","weight":0.1374},{"period":"ytd","weight":0.0007}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"GRI Bio, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that develops as an oral therapeutic for liver disease. GRI Bio, Inc. was formerly know as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in La Jolla, California.","exchange":"NASDAQ","name":"GRI BIO INC","nameEN":"GRI BIO INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"GRI BIO INC(GRI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest GRI BIO INC(GRI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"GRI BIO INC,GRI,GRI BIO INC股票,GRI BIO INC股票老虎,GRI BIO INC股票老虎国际,GRI BIO INC行情,GRI BIO INC股票行情,GRI BIO INC股价,GRI BIO INC股市,GRI BIO INC股票价格,GRI BIO INC股票交易,GRI BIO INC股票购买,GRI BIO INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"GRI BIO INC(GRI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest GRI BIO INC(GRI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}